Boothbay Fund Management LLC acquired a new stake in Enhabit, Inc. (NYSE:EHAB – Get Rating) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 21,262 shares of the company’s stock, valued at approximately $299,000.
Several other hedge funds and other institutional investors have also recently made changes to their positions in EHAB. Bessemer Group Inc. acquired a new stake in shares of Enhabit in the third quarter valued at about $26,000. CI Investments Inc. acquired a new stake in shares of Enhabit in the second quarter valued at about $27,000. IFP Advisors Inc purchased a new position in Enhabit during the 3rd quarter valued at about $39,000. South Dakota Investment Council purchased a new position in Enhabit during the 3rd quarter valued at about $45,000. Finally, KBC Group NV purchased a new position in Enhabit during the 3rd quarter valued at about $54,000. Institutional investors and hedge funds own 95.55% of the company’s stock.
Analyst Upgrades and Downgrades
EHAB has been the subject of several recent research reports. Credit Suisse Group restated a “neutral” rating and set a $15.00 target price on shares of Enhabit in a report on Thursday, February 16th. Stifel Nicolaus raised their target price on shares of Enhabit from $17.00 to $18.00 in a report on Wednesday, February 15th. Citigroup raised their target price on shares of Enhabit from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, February 17th. CJS Securities started coverage on shares of Enhabit in a report on Tuesday, December 13th. They set a “market perform” rating and a $18.00 target price for the company. Finally, UBS Group started coverage on shares of Enhabit in a report on Thursday, December 8th. They set a “sell” rating and a $12.00 price target for the company. Two analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Enhabit currently has a consensus rating of “Hold” and a consensus price target of $16.71.
Enhabit Stock Down 0.1 %
About Enhabit
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Recommended Stories
- Get a free copy of the StockNews.com research report on Enhabit (EHAB)
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
- Taiwan Semiconductor Manufacturing Expanding in the West
Want to see what other hedge funds are holding EHAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enhabit, Inc. (NYSE:EHAB – Get Rating).
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.